Search

everythinglearnresearchcommunity

for

Search:↓

A new treatment using a special gel with miR-665 reduces inflammation and helps hair regrow in alopecia areata.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.

Olumiant should be covered for severe alopecia areata if certain conditions are met.

Adalimumab helped control a child's severe eye disease when other treatments failed.

A 13-year-old girl with various symptoms was successfully treated for autoimmune disease using the antibiotic co-trimoxazole.

Adalimumab improved folliculitis decalvans in most patients.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.

The new micelle formulation delivers acne treatment more effectively and safely than current gels.

JAK inhibitors may help treat alopecia areata by reversing hair loss.

Deucravacitinib may help treat various immune diseases beyond psoriasis, but more research is needed.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Early diagnosis and treatment are crucial for CAPS, and Eculizumab can be effective.

Careful monitoring is crucial to prevent JC virus reactivation in lupus patients treated with rituximab.

Psoriasis patients are willing to pay less than the cost of biologic treatments for remission and don't expect complete or long-term symptom clearance.

Tofacitinib may be an effective and safe treatment for adolescent alopecia areata.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.

Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.

Individualized treatments may help manage Dercum's disease symptoms.

Many patients in the rheumatology clinic adjusted or stopped their medications due to side effects.

Upadacitinib effectively treated a patient with multiple inflammatory conditions.

Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.

Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Ixekizumab is safe for long-term use with low rates of major heart-related events.

The fish oil-based gel with imiquimod improves skin cancer treatment and reduces inflammation.